Selectivity in JAK Inhibition: Balancing Efficacy and Safety
The Shift Toward Selectivity in JAK Inhibitors
A Family of Four Enzymes
The Janus kinase family is made up of four members, named JAK1, JAK2, JAK3, and TYK2. Each enzyme pairs with a different receptor on the cell surface and orchestrates signals for distinct groups of inflammatory messengers called cytokines. Broadly speaking, JAK1 partners with receptors for many interleukins that drive inflammation, as well as the receptors for interferons. JAK2 is critical for signals from hormones like erythropoietin and thrombopoietin, which control red blood cell and platelet production, along with some inflammatory cytokines. JAK3 pairs only with receptors for cytokines that rely on a shared component called the common gamma chain, which are vital for the development and function of immune cells. TYK2 works alongside JAK1 for interferon signaling and with other receptors for interleukins such as IL-12 and IL-23. Understanding these different roles has allowed researchers to design more selective medications, with the aim of preserving benefit while sidestepping certain side effects linked to blocking the wrong enzyme.
From Broad Blockers to Targeted Agents
The earliest JAK inhibitors, such as tofacitinib and baricitinib, act on multiple JAK enzymes. Tofacitinib primarily inhibits JAK1 and JAK3, with lesser activity against JAK2. Baricitinib blocks JAK1 and JAK2. Because these drugs touch JAK2, they can interfere with the signaling of erythropoietin and thrombopoietin, which helps explain the drops in hemoglobin and platelet counts sometimes seen in patients. Newer agents were designed to be more selective. Upadacitinib and filgotinib were engineered to strongly favor JAK1, sparing JAK2 and JAK3 to a meaningful degree. By avoiding JAK2 inhibition, these drugs aim to reduce the risk of anemia and platelet changes without sacrificing anti-inflammatory power. The TYK2 inhibitor deucravacitinib represents a further step. It is not a traditional JAK inhibitor that binds the active site of the enzyme; instead, it locks onto a regulatory region of the TYK2 molecule, distorting its shape and preventing it from sending signals. This unique mode of action spares JAK1, JAK2, and JAK3 entirely.
How Selectivity Changes the Safety Conversation
The drive for selectivity is not just theoretical. In clinical trials and real-world use, JAK1-selective agents have shown good efficacy while producing a laboratory profile that appears distinct from less selective drugs. The decline in hemoglobin and neutrophil counts is generally less pronounced with upadacitinib and filgotinib compared to earlier JAK inhibitors. This does not mean selective agents are free from serious risks. The major concerns that apply to the class, including serious infections, reactivation of the herpes zoster virus causing shingles, blood clots, and changes in cholesterol, persist. However, some differences are emerging. A pooled analysis of filgotinib clinical trials indicated a low rate of deep vein thrombosis and pulmonary embolism, although surveillance continues. Deucravacitinib, by bypassing the classic JAK pathways, has not shown the same laboratory changes in platelets or red blood cells, and its safety profile in psoriasis studies did not raise the blood clot or cardiovascular signals linked to some other JAK inhibitors. Researchers caution that longer follow-up is needed to fully understand whether selectivity truly changes the risk of rare but serious events.
Topical JAK Inhibition as a Local Approach
Another direction in the field is the development of topical formulations that act only on the skin, minimizing the amount of drug that enters the bloodstream. A topical cream containing ruxolitinib, an inhibitor of JAK1 and JAK2, has been approved for the treatment of mild to moderate atopic dermatitis and for non-segmental vitiligo. Because the cream is applied directly to affected skin, systemic exposure is very low. In clinical trials, blood levels of ruxolitinib were minimal, and the laboratory changes seen with oral JAK inhibitors, such as reductions in blood cell counts, were not observed. The side effects most commonly reported with the cream have been local reactions like burning, itching, or redness at the application site. This localized treatment offers a useful option for patients who might not need or cannot tolerate systemic therapy, though it is not suitable for very widespread or severe disease.
JAK Inhibition in Myeloproliferative Diseases
The story of JAK inhibitors extends beyond autoimmune and inflammatory conditions into disorders where the bone marrow makes too many blood cells. In myelofibrosis, a type of chronic leukemia, a mutation in the JAK2 gene drives uncontrolled signaling, leading to an enlarged spleen, severe fatigue, and systemic inflammation. Ruxolitinib and fedratinib, both acting as JAK2 inhibitors, are approved for this disease. They work primarily by tamping down the overactive JAK-STAT pathway that fuels the cancer. While they shrink the spleen and improve debilitating symptoms, they do not eliminate the mutated clone and can cause their own set of side effects, including anemia and low platelet counts, which are already problems in this disease. In polycythemia vera, another disorder marked by excessive red blood cell production and often driven by a JAK2 mutation, ruxolitinib is used when first-line therapies fail. These uses highlight how the same biological pathway can be hijacked by different disease processes, and how JAK inhibition can be tailored accordingly.
The Future of JAK Inhibition
Research continues into even more precise inhibitors, as well as into ways to combine JAK inhibitors with other treatments. Ongoing studies are evaluating whether selective agents can safely be used in earlier lines of treatment, and whether the cardiovascular and clotting risks observed with some drugs in older, high-risk populations apply equally to younger patients without those risk factors. The development of TYK2 inhibitors like deucravacitinib opens a door to a new molecular class that shares downstream effects with classic JAK inhibitors while offering a distinct safety fingerprint. Meanwhile, regulatory agencies maintain that the class-wide boxed warnings will be adjusted only if long-term data provide compelling evidence that certain drugs carry meaningfully lower risk. In the clinic, the expanding array of JAK pathway inhibitors means treatment decisions can increasingly be tailored to a person’s specific disease, risk factor profile, and route of drug delivery.
Sources
Schwartz DM, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nature Reviews Drug Discovery. 2017;16:843-862.
Gadina M, et al. Translational and clinical advances in JAK-STAT biology. Nature Reviews Rheumatology. 2021;17:395-412.
Taylor PC, et al. JAK inhibitors for the treatment of rheumatoid arthritis: a comparative safety perspective. Expert Opinion on Drug Safety. 2022;21:1371-1394.
Papp K, et al. Efficacy and safety of topical ruxolitinib cream for the treatment of atopic dermatitis: results from two phase 3 studies. Journal of the American Academy of Dermatology. 2021;85:863-872.
Verstovsek S, et al. Safety and efficacy of ruxolitinib in myelofibrosis: a 5-year analysis of the COMFORT-I trial. New England Journal of Medicine. 2017;376:1251-1262.
Armstrong AW, et al. Deucravacitinib versus placebo and apremilast in plaque psoriasis. New England Journal of Medicine. 2023;388:1397-1408.
(Source : DeepSeek)
/image%2F3334645%2F20201111%2Fob_fd07bb_sans-titre-1.jpg)
/image%2F3334645%2F20260726%2Fob_276c88_7a21ff63-258b-4d58-b483-439b5b1d01c6.jpg)
/image%2F3334645%2F20260725%2Fob_250931_oig1.jpg)
/image%2F3334645%2F20260724%2Fob_ae949a_jul-24-2026-12-04-33-pm.png)
/image%2F3334645%2F20260724%2Fob_94a63a_oig3.jpg)
/image%2F3334645%2F20260709%2Fob_f4fa78_chatgpt-image-jul-9-2026-08-33-47-pm.png)
/image%2F3334645%2F20260709%2Fob_a989ec_0cf6a98f-1efb-4e23-95b3-646be2dbe10d.jpg)
/image%2F3334645%2F20260708%2Fob_db26eb_d807487f-eb51-42c3-8ffd-f9155df8113d.jpg)
/image%2F3334645%2F20260706%2Fob_f7d9f9_aqpoh6vxgl94osb5iikdk3ghpk-v67yvci3ngg.jpg)